KETOCONAZOLE THERAPY OF PROGRESSIVE COCCIDIOIDOMYCOSIS - COMPARISON OF 400-MG AND 800-MG DOSES AND OBSERVATIONS AT HIGHER DOSES
KETOCONAZOLE THERAPY OF PROGRESSIVE COCCIDIOIDOMYCOSIS - COMPARISON OF 400-MG AND 800-MG DOSES AND OBSERVATIONS AT HIGHER DOSES
复制标题
DOI：
10.1016/0002-9343(88)90143-x
复制
发表时间：
1988-03-01
影响因子：
5.9
通讯作者：
CLOUD, GA
中科院分区：
文献类型：
--
作者：
GALGIANI, JN;STEVENS, DA;CLOUD, GA
112 名患有粗球孢子菌引起的进行性肺部、骨骼或软组织感染的患者被随机分配接受每天 400 或 800 毫克剂量的酮康唑治疗。在治疗期间，如果反应不令人满意，则方案提供更高剂量的治疗。 400 mg 酮康唑治疗的成功率为 23.2%，与 800 mg 治疗的 32.1% 成功率相似 (p = 0.29)。 23 名初始治疗失败的患者中，另外 6 名后来每天接受 1,200 或 1,600 毫克酮康唑治疗的患者也出现了改善。然而，在成功完成疗程的患者中，那些需要高于 400 毫克剂量才能成功的患者复发的频率更高。从这些研究得出的结论是，高于目前推荐剂量的酮康唑对大多数非脑膜型球孢子菌病患者几乎没有益处或没有益处。
One hundred and twelve patients with progressive pulmonary, skeletal, or soft tissue infections caused by Coccidioides immitis were randomly assigned to treatment with 400 or 800 mg per day dosages of ketoconazole. During therapy, if response was unsatisfactory, the protocol provided for treatment with higher doses. With 400 mg, ketoconazole resulted in 23.2 percent successes, which was similar to 32.1 percent successes with 800-mg treatments (p = 0.29). An additional six of 23 patients in whom initial therapy failed and who later received 1,200 or 1,600 mg per day of ketoconazole also showed improvement. However, among patients completing successful courses of therapy, relapses were more frequent in those requiring higher than 400-mg dosages for their success. From these studies, it is concluded that ketoconazole in doses above those currently recommended offer little or no benefit for most patients with non-meningeal forms of coccidioidomycosis.